Haoqiang Ying, M.D., Ph.D.
Department of Molecular and Cellular Oncology, Division of Discovery Science
About Dr. Haoqiang Ying
My research for the past decade has been focusing on the pathogenesis of pancreatic ductal adenocarcinoma
(PDAC) using genetically engineered mouse models. My medical training helps me to understand the
pathophysiology and current therapeutic needs of this lethal disease. I have accumulated extensive experience
in studying the biology and underlying mechanism of pancreatic cancer using various in vivo and ex vivo model
systems. My work in this field has helped us understand the roles of KRAS oncogene and its surrogates during
PDAC development and maintenance. My work was one of the first to report the critical role of YAP1 oncogene
for the bypass of KRAS-addiction in PDAC and drive tumor growth in the squamous subtype. These works
start to illuminate the molecular underpinning for the tumor heterogeneity and potential mechanisms for the
acquired resistance to KRAS-targeted therapy in pancreatic cancer. Most recently, our work identified
proteostasis as a critical cell-autonomous mechanism and CD24-mediated immune-mediated mechanism for
the acquired resistance to KRAS targeted therapy which can be therapeutically targeted. Another major focus
of my research is to understand and target the metabolism vulnerabilities of PDAC. In particular, my work
established the critical function of KRAS-driven glucose metabolism during PDAC maintenance and elucidated
how KRAS promotes the flux of glycolysis intermediates into anabolic pathways, such as hexosamine
biosynthesis pathway and non-oxidative pentose phosphate pathway to sustain tumor growth. We further
demonstrated the therapeutic potential of co-targeting metabolism pathways and KRAS signaling surrogates in
PDAC preclinical models.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Molecular Oncology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2007 | Boston University School of Medicine, Boston, Massachusetts, US, Ph.D. in Biochemistry |
| 2000 | Peking Union Medical College, Beijing, US, MD |
Postgraduate Training
| 2006-2010 | Research Fellowship, Dana-Farber Cancer Institute, Boston, Massachusetts |
Experience & Service
Intramural Institutional Committee Activities
Member, MCO chair search advisory committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Member, Organizing Committee for the 2017 Symposium on Cancer Research, The University of Texas MD Anderson Cancer Center, 2016 - 2016
Extramural Institutional Committee Activities
Chair, GSBS Membership Committee, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Member, GSBS Executive Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, the Research Enablement, Activities and Conduct Team (REACT), The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, GSBS Cancer Biology Program Seering Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, GSBS Membership Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2024
Member, Odyssey Program Advisory Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, GSBS Student Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022
Reviewer, GSBS Presidents Research Scholarship selection committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Reviewer, Review Committee for MD Anderson Alfred G. Knudson, Jr., Award for the best GSBS dissertation, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, MCO Distinguished Seminar Series, The University of Texas MD Anderson Cancer Center, 2019 - Present
Ad hoc reviewer, GSBS Student Scholarship Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2019
Member, HEIPSCRO, The University of Texas MD Anderson Cancer Center, 2016 - Present
Editorial Activities
Editor, Cells, 2021 - Present
Honors & Awards
| 2024 | Andrew Sabin Family Foundation Award, Andrew Sabin Family Foundation |
| 2020 | Peter Bradley Carlson Trust Award, Peter Bradley Carlson Trust |
| 2017 - 2019 | Pancreatic Cancer Action Network-AACR Career Development Award, Pancreatic Cancer Action Network-AACR |
| 2009 - 2010 | GI SPORE Career Development Award, Dana Farber/Harvard Cancer Center |
| 2007 - 2009 | Marsha Mae Moeslein Fellowship, American Brain Tumor Association |
| 2006 | Henry I. Russek Graduate Student Achievement Award, Boston University School of Medicine |
| 2004 - 2006 | Predoctoral Traineeship Award, Department of Defense Breast Cancer Research Program |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Targeting KRAS oncogene in pancreatic cancer. Invited. Translational Molecular Pathology Annual Retreat. Houston, Texas, US.
- 2025. Targeting KRAS oncogene in pancreatic cancer. Invited. Houston, Texas, US.
- 2023. Combination Strategy Targeting KRAS-Driven GI Cancer, US.
- 2022. Ether lipid is required for redox homeostasis in pancreatic cancer, US.
- 2022. Metabolism Dependency of Pancreatic Cancer. Invited. Houston, Texas, US.
- 2022. Metabolism Dependency of Pancreatic Cancer. Invited. Houston, Texas, US.
- 2019. The function of YAP1 oncogene as a context-specific driver in pancreatic cancer. Houston, Texas, US.
- 2017. The function of YAP1 oncogene during pancreatic cancer development. Invited. Houston, Texas, US.
- 2015. Kras oncogene and the maintenance of pancreatic cancer. Invited. Houston, Texas, US.
National Presentations
- 2022. Metabolism Dependency of Pancreatic Cancer. Invited. New Orleans, LA, US.
International Presentations
- 2024. CD24 Upregulation Drives Resistance to KRAS Inhibitor Therapy in Preclinical Models of Pancreatic Cancer. Poster. Amercian Pancreatic Association Annual Meeting, US.
- 2023. Metabolism adaptation in pancreatic ductal adenocarcinoma. Invited. Amercian Pancreatic Association Annual Meeting. San Diego, US.
- 2022. Understanding and targeting KRAS oncogene in pancreatic cancer. Invited. Nagoya, JP.
- 2022. Ether phospholipid is required for mitochondrial ROS homeostasis in pancreatic cancer. Invited. Japanese Cancer Association Annual Meeting. Okahoma, JP.
- 2022. KRAS-driven mannose metabolism sustains lysosome function in pancreatic cancer. Conference. AACR Special Conference on Targeting RAS. Orlando, US.
- 2014. Yap1 activation enables bypass of oncogenic K-RAS addiction in pancreatic cancer. Invited. AACR Special Conference on RAS Oncogene. Orlando, US.
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Targeting tumor-macrophage crosstalk in KRAS-driven pancreatic cancer |
| Funding Source: | Andrew Sabin Family Fellows Program |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Targeting Acquired Resistance to KRAS Inhibitors in Pancreatic Cancer |
| Funding Source: | DOD |
| Role: | PI |
| ID: | PA220245 |
| Date: | 2023 - 2026 |
| Title: | A Novel Therapeutic Strategy Targeting Pancreatic Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP230050 |
| Date: | 2023 - 2026 |
| Title: | Enhancing Immune Responses in Pancreatic Cancer by Stromal Inhibition of HIF2 |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP230224 |
| Date: | 2023 - 2027 |
| Title: | The Role of HIF2 in Pancreatic Ductal Adenocarcinoma |
| Funding Source: | NCI |
| Role: | Co-I |
| ID: | R01CA269565 |
| Date: | 2022 - 2027 |
| Title: | Targeting Acquired Resistance in KRAS Driven Cancers |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1R01CA27274 |
| Date: | 2022 - 2025 |
| Title: | IRE-based Rational Combination for Effective PDAC Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| ID: | RP220051 |
| Date: | 2022 - 2025 |
| Title: | Alteration of mannose metabolism in lung cancer |
| Funding Source: | American Cancer Society (ACS) |
| Role: | CO-I |
| ID: | RSG-21-153-01-CCB |
| Date: | 2021 - 2026 |
| Title: | Genetics and Biology of Pancreatic Ductal Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Program Leader |
| ID: | 2-P01-CA117969-11 |
| Date: | 2020 - 2024 |
| Title: | WNT/beta-catenin signaling in pancreatic oncogenesis |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 5R01CA220236 |
| Date: | 2019 - 2024 |
| Title: | Elucidating and targeting subtype-specific driver in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA214793 |
Selected Publications
Peer-Reviewed Articles
- Wei Y, Liu M, Yen EY, Yao J, Xun Z, Nguyen PT, Wang X, Yang Z, Yousef A, Pan D, Jin Y, Li CF, Theardy MS, Park J, Cai Y, Takeda M, Vasquez M, Park EM, Peng DH, Zhou Y, Zhao H, Heffernan TP, Viale A, Wang H, Watowich SS, Liang H, Zhao D, DePinho RA, Yao W, Ying H. KRAS Inhibition Activates an Actionable CD24 "Don't Eat Me" Signal in Pancreatic Cancer. Cancer Res, 2025. e-Pub 2025. PMID: 40966362.
- Theardy, MS, Takeda, M, Sorokin, A, Chen, S, Yang, Z, Wang, X, Kanikarla, PM, Coker, O, Nguyen, P, Wei, Y, Yao, J, Yan, L, Jin, Y, Cai, Y, Paku, M, Chen, Z, Li, KZ, Citron, F, Tomihara, H, Gao, S, Deem, AK, Zhao, J, Wang, H, Hanash, S, DePinho, RA, Maitra, A, Draetta, G, Ying, H, Kopetz, S, Yao, W. Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell Reports Medicine 6(8), 2025. e-Pub 2025. PMID: 40713971.
- Saito Y, Xiao Y, Yao J, Li Y, Liu W, Yuzhalin AE, Shyu YM, Li H, Yuan X, Li P, Zhang Q, Li Z, Wei Y, Yin X, Zhao J, Kariminia SM, Wu YC, Wang J, Yang J, Xia W, Sun Y, Jho EH, Chiao PJ, Hwang RF, Ying H, Wang H, Zhao Z, Maitra A, Hung MC, DePinho RA, Yu D. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Cell Discov 10(1):109, 2024. e-Pub 2024. PMID: 39468013.
- Li CF, Bai LY, Wei Y, Lee HH, Yang R, Yao J, Wang H, Wang YN, Chang WC, Shen YC, Wang SC, Chou CW, Fu J, Ling J, Chu YY, Chiu CF, Wang M, Yu D, Chiao PJ, Liang H, Maitra A, Ying H, Hung MC. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer. bioRxiv, 2024. e-Pub 2024. PMID: 39484589.
- Balachandran Pillai A, Yousef M, Yousef A, Alfaro-Munoz KD, Smaglo BG, Willis J, Wolff RA, Pant S, Hurd MW, Maitra A, Wang H, Katz MHG, Prakash LR, Tzeng CD, Snyder R, Castelnovo LF, Chen A, Kravets A, Kudriavtseva K, Tarasov A, Kryukov K, Ying H, Shen JP, Zhao D. Molecular and Clinical Features of Pancreatic Acinar Cell Carcinoma: A Single-Institution Case Series. Cancers (Basel) 16(19), 2024. e-Pub 2024. PMID: 39410042.
- Takeda M, Theardy MS, Sorokin A, Coker O, Kanikarla P, Chen S, Yang Z, Nguyen P, Wei Y, Yao J, Wang X, Yan L, Jin Y, Cai Y, Paku M, Chen Z, Li KZ, Citron F, Tomihara H, Gao S, Deem AK, Zhao J, Wang H, Hanash S, DePinho RA, Maitra A, Draetta GF, Ying H, Kopetz S, Yao W. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv, 2024. e-Pub 2024. PMID: 39211217.
- Arora N, Liang H, Yao W, Ying H, Liu J, Zhou Y. Lysophosphatidylcholine acyltransferase 1 suppresses nanoclustering and function of KRAS. bioRxiv, 2024. e-Pub 2024. PMID: 38853864.
- Ho IL, Li CY, Wang F, Zhao L, Liu J, Yen EY, Dyke CA, Shah R, Liu Z, Cetin AO, Chu Y, Citron F, Attanasio S, Corti D, Darbaniyan F, Del Poggetto E, Loponte S, Liu J, Soeung M, Chen Z, Jiang S, Jiang H, Inoue A, Gao S, Deem A, Feng N, Ying H, Kim M, Giuliani V, Genovese G, Zhang J, Futreal A, Maitra A, Heffernan T, Wang L, Do KA, Gargiulo G, Draetta G, Carugo A, Lin R, Viale A. Clonal dominance defines metastatic dissemination in pancreatic cancer. Sci Adv 10(11):eadd9342, 2024. e-Pub 2024. PMID: 38478609.
- Wei Y, Liu M, Yen EY, Yao J, Nguyen PT, Wang X, Yang Z, Yousef A, Pan D, Jin Y, Theady MS, Park J, Cai Y, Takeda M, Vasquez M, Zhou Y, Zhao H, Viale A, Wang H, Zhao D, DePinho RA, Yao W, Ying H. KRAS inhibition activates an actionable CD24 'don't eat me' signal in pancreas cancer. bioRxiv, 2023. e-Pub 2023. PMID: 37790498.
- Mahadevan KK, LeBleu VS, Ramirez EV, Chen Y, Li B, Sockwell AM, Gagea M, Sugimoto H, Sthanam LK, Tampe D, Zeisberg M, Ying H, Jain AK, DePinho RA, Maitra A, McAndrews KM, Kalluri R. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells. Dev Cell 58(17):1562-1577.e8, 2023. e-Pub 2023. PMID: 37625403.
- Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Paradiso F, Sugimoto H, Arian KA, Ying H, Barekatain Y, Sthanam LK, Kelly PJ, Maitra A, Heffernan TP, Kalluri R. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 41(9):1606-1620.e8, 2023. e-Pub 2023. PMID: 37625401.
- Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, Chang EC, Catic A, Lin X, Miles G, Huang P, Sun Z, Burt B, Wang H, Wang J, Yao QC, Zhang B, Roth JA, O'Malley BW, Ellis MJ, Rimawi MF, Ying H, Chen X. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381(6662):eabn4180, 2023. e-Pub 2023. PMID: 37676964.
- Chen Z, Ho IL, Soeung M, Yen EY, Liu J, Yan L, Rose JL, Srinivasan S, Jiang S, Edward Chang Q, Feng N, Gay JP, Wang Q, Wang J, Lorenzi PL, Veillon LJ, Wei B, Weinstein JN, Deem AK, Gao S, Genovese G, Viale A, Yao W, Lyssiotis CA, Marszalek JR, Draetta GF, Ying H. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nat Commun 14(1):2194, 2023. e-Pub 2023. PMID: 37069167.
- Li F, Wang Y, Hwang I, Jang JY, Xu L, Deng Z, Yu EY, Cai Y, Wu C, Han Z, Huang YH, Huang X, Zhang L, Yao J, Lue NF, Lieberman PM, Ying H, Paik J, Zheng H. Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance. Nat Commun 14(1):1756, 2023. e-Pub 2023. PMID: 36991019.
- Sun C, Ye Y, Tan Z, Liu Y, Li Y, Hu W, Liang K, Egranov SD, Huang LA, Zhang Z, Zhang Y, Yao J, Nguyen TK, Zhao Z, Wu A, Marks JR, Caudle AS, Sahin AA, Gao J, Gammon ST, Piwnica-Worms D, Hu J, Chiao PJ, Yu D, Hung MC, Curran MA, Calin GA, Ying H, Han L, Lin C, Yang L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Sci Adv 9(5):eadd6995, 2023. e-Pub 2023. PMID: 36724291.
- Gulhati P, Schalck A, Jiang S, Shang X, Wu CJ, Hou P, Ruiz SH, Soto LS, Parra E, Ying H, Han J, Dey P, Li J, Deng P, Sei E, Maeda DY, Zebala JA, Spring DJ, Kim M, Wang H, Maitra A, Moore D, Clise-Dwyer K, Wang YA, Navin NE, DePinho RA. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Nat Cancer 4(1):62-80, 2023. e-Pub 2023. PMID: 36585453.
- Yuan M, Tu B, Li H, Pang H, Zhang N, Fan M, Bai J, Wang W, Shu Z, DuFort CC, Huo S, Zhai J, Yao K, Wang L, Ying H, Zhu WG, Fu D, Hu Z, Zhao Y. Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth. Nat Cancer 3(8):945-960, 2022. e-Pub 2022. PMID: 35982178.
- Kerk SA, Lin L, Myers AL, Sutton DJ, Andren A, Sajjakulnukit P, Zhang L, Zhang Y, Jimenez JA, Nelson BS, Chen B, Robinson A, Thurston G, Kemp SB, Steele NG, Hoffman MT, Wen HJ, Long D, Ackenhusen SE, Ramos J, Gao X, Nwosu ZC, Galban S, Halbrook CJ, Lombard DB, Piwnica-Worms DR, Ying H, Pasca di Magliano M, Crawford HC, Shah YM, Lyssiotis CA. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife 11, 2022. e-Pub 2022. PMID: 35815941.
- Yuan X, Duan Y, Xiao Y, Sun K, Qi Y, Zhang Y, Ahmed Z, Moiani D, Yao J, Li H, Zhang L, Yuzhalin AE, Li P, Zhang C, Badu-Nkansah A, Saito Y, Liu X, Kuo WL, Ying H, Sun SC, Chang JC, Tainer JA, Yu D. Vitamin E Enhances Cancer Immunotherapy by Reinvigorating Dendritic Cells via Targeting Checkpoint SHP1. Cancer Discov 12(7):1742-1759, 2022. e-Pub 2022. PMID: 35420681.
- Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, Liu C, Hsu JL, Chang WC, Yang R, Chan LC, Qu J, Zhang S, Ying H, Yu D, Hung MC. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Res 82(11):2185-2195, 2022. e-Pub 2022. PMID: 35385574.
- Liu Y, Deguchi Y, Wei D, Liu F, Moussalli MJ, Deguchi E, Li D, Wang H, Valentin LA, Colby JK, Wang J, Zheng X, Ying H, Gagea M, Ji B, Shi J, Yao JC, Zuo X, Shureiqi I. Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARdelta. Nat Commun 13(1):2665, 2022. e-Pub 2022. PMID: 35562376.
- Kim PK, Halbrook CJ, Kerk SA, Radyk M, Wisner S, Kremer DM, Sajjakulnukit P, Andren A, Hou SW, Trivedi A, Thurston G, Anand A, Yan L, Salamanca-Cardona L, Welling SD, Zhang L, Pratt MR, Keshari KR, Ying H, Lyssiotis CA. Hyaluronic acid fuels pancreatic cancer cell growth. Elife 10, 2021. e-Pub 2021. PMID: 34951587.
- Deng Y, Xia X, Zhao Y, Zhao Z, Martinez C, Yin W, Yao J, Hang Q, Wu W, Zhang J, Yu Y, Xia W, Yao F, Zhao D, Sun Y, Ying H, Hung MC, Ma L. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nat Commun 12(1):7041, 2021. e-Pub 2021. PMID: 34873175.
- Yan H, Yu CC, Fine SA, Youssof AL, Yang YR, Yan J, Karg DC, Cheung EC, Friedman RA, Ying H, Chen EI, Luo J, Miao Y, Qiu W, Su GH. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1. Oncogene 40(50):6759-6771, 2021. e-Pub 2021. PMID: 34663879.
- Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett 517:66-77, 2021. e-Pub 2021. PMID: 34111513.
- Del Poggetto E, Ho IL, Balestrieri C, Yen EY, Zhang S, Citron F, Shah R, Corti D, Diaferia GR, Li CY, Loponte S, Carbone F, Hayakawa Y, Valenti G, Jiang S, Sapio L, Jiang H, Dey P, Gao S, Deem AK, Rose-John S, Yao W, Ying H, Rhim AD, Genovese G, Heffernan TP, Maitra A, Wang TC, Wang L, Draetta GF, Carugo A, Natoli G, Viale A. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science 373(6561):eabj0486, 2021. e-Pub 2021. PMID: 34529467.
- Yan L, Tu B, Yao J, Gong J, Carugo A, Bristow CA, Wang Q, Zhu C, Dai B, Kang Y, Han L, Feng N, Jin Y, Fleming J, Heffernan TP, Yao W, Ying H. Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition. Cancer Res 81(15):4054-4065, 2021. e-Pub 2021. PMID: 34117030.
- Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun 12(1):4626, 2021. e-Pub 2021. PMID: 34330913.
- Oh H, Hwang I, Jang JY, Wu L, Cao D, Yao J, Ying H, Li JY, Yao Y, Hu B, Wang Q, Zheng H, Paik J. Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling. Cancer Res 81(6):1528-1539, 2021. e-Pub 2021. PMID: 33509942.
- Maitituoheti M, Keung EZ, Tang M, Yan L, Alam H, Han G, Singh AK, Raman AT, Terranova C, Sarkar S, Orouji E, Amin SB, Sharma S, Williams M, Samant NS, Dhamdhere M, Zheng N, Shah T, Shah A, Axelrad JB, Anvar NE, Lin YH, Jiang S, Chang EQ, Ingram DR, Wang WL, Lazar A, Lee MG, Muller F, Wang L, Ying H, Rai K. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep 33(3):108293, 2020. e-Pub 2020. PMID: 33086062.
- Wu X, Park M, Sarbassova DA, Ying H, Lee MG, Bhattacharya R, Ellis L, Peterson CB, Hung MC, Lin HK, Bersimbaev RI, Song MS, Sarbassov DD. A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. Int J Cancer 146(10):2822-2828, 2020. e-Pub 2020. PMID: 31472018.
- Dey P, Li J, Zhang J, Chaurasiya S, Strom A, Wang H, Liao WT, Cavallaro F, Denz P, Bernard V, Yen EY, Genovese G, Gulhati P, Liu J, Chakravarti D, Deng P, Zhang T, Carbone F, Chang Q, Ying H, Shang X, Spring DJ, Ghosh B, Putluri N, Maitra A, Wang YA, DePinho RA. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov 10(4):608-625, 2020. e-Pub 2020. PMID: 32046984.
- Chou CW, Yang RY, Chan LC, Li CF, Sun L, Lee HH, Lee PC, Sher YP, Ying H, Hung MC. The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer. Am J Cancer Res 10(8):2621-2634, 2020. e-Pub 2020. PMID: 32905506.
- Singh K, Pruski MA, Polireddy K, Jones NC, Chen Q, Yao J, Dar WA, McAllister F, Ju C, Eltzschig HK, Younes M, Moran C, Karmouty-Quintana H, Ying H, Bailey JM. Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer. Oncogene 39(5):1152-1164, 2020. e-Pub 2020. PMID: 31570790.
- Tu B, Yao J, Ferri-Borgogno S, Zhao J, Chen S, Wang Q, Yan L, Zhou X, Zhu C, Bang S, Chang Q, Bristow CA, Kang Y, Zheng H, Wang H, Fleming JB, Kim M, Heffernan TP, Draetta GF, Pan D, Maitra A, Yao W, Gupta S, Ying H. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma. JCI Insight 4(21), 2019. e-Pub 2019. PMID: 31557131.
- Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, Vladimirova O, Xu L, Yang L, Lu B, Dheekollu J, Li JY, Feng H, Hu J, Vakoc CR, Ying H, Paik J, Lieberman PM, Zheng H. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J 38(19):e96659, 2019. e-Pub 2019. PMID: 31454099.
- Yu M, Nguyen ND, Huang Y, Lin D, Fujimoto TN, Molkentine JM, Deorukhkar A, Kang Y, San Lucas FA, Fernandes CJ, Koay EJ, Gupta S, Ying H, Koong AC, Herman JM, Fleming JB, Maitra A, Taniguchi CM. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight 5(16), 2019. e-Pub 2019. PMID: 31335325.
- Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med 25(4):628-640, 2019. e-Pub 2019. PMID: 30833752.
- Yao W, Rose JL, Wang W, Seth S, Jiang H, Taguchi A, Liu J, Yan L, Kapoor A, Hou P, Chen Z, Wang Q, Nezi L, Xu Z, Yao J, Hu B, Pettazzoni PF, Ho IL, Feng N, Ramamoorthy V, Jiang S, Deng P, Ma GJ, Den P, Tan Z, Zhang SX, Wang H, Wang YA, Deem AK, Fleming JB, Carugo A, Heffernan TP, Maitra A, Viale A, Ying H, Hanash S, DePinho RA, Draetta GF. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature 568(7752):410-414, 2019. e-Pub 2019. PMID: 30918400.
- Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, Wang X, Bronson RT, Lyssiotis CA, Ying H, Kimmelman AC. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9(1):4945, 2018. e-Pub 2018. PMID: 30470748.
- Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, Zhou J, Zhou Y, Marks JR, Hawke DH, Hung MC, Yang L, Han L, Ying H, Lin C. Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res 78(16):4524-4532, 2018. e-Pub 2018. PMID: 29967256.
- Zhao N, Cao J, Xu L, Tang Q, Dobrolecki LE, Lv X, Talukdar M, Lu Y, Wang X, Hu DZ, Shi Q, Xiang Y, Wang Y, Liu X, Bu W, Jiang Y, Li M, Gong Y, Sun Z, Ying H, Yuan B, Lin X, Feng XH, Hartig SM, Li F, Shen H, Chen Y, Han L, Zeng Q, Patterson JB, Kaipparettu BA, Putluri N, Sicheri F, Rosen JM, Lewis MT, Chen X. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer. J Clin Invest 128(4):1283-1299, 2018. e-Pub 2018. PMID: 29480818.
- Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8, 2018. e-Pub 2018. PMID: 29606349.
- Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
- Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH, Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 8:14437, 2017. e-Pub 2017. PMID: 28232723.
- Dey P, Baddour J, Muller F, Wu CC, Wang H, Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, Fleming J, Satani N, Zhao D, Achreja A, Yang L, Lee J, Chang E, Genovese G, Viale A, Ying H, Draetta G, Maitra A, Wang YA, Nagrath D, DePinho RA. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542(7639):119-123, 2017. e-Pub 2017. PMID: 28099419.
- Chen CT, Chen YC, Du Y, Han Z, Ying H, Bouchard RR, Hsu JL, Hsu JM, Mitcham TM, Chen MK, Sun HL, Chang SS, Li D, Chang P, DePinho RA, Hung MC. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. Am J Cancer Res 7(3):657-672, 2017. e-Pub 2017. PMID: 28401019.
- Jiang X, Niu M, Chen D, Chen J, Cao Y, Li X, Ying H, Bergholz J, Zhang Y, Xiao ZX. Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF. Oncotarget 7(31):49180-49193, 2016. e-Pub 2016. PMID: 27341132.
- Sousa CM, Biancur DE, Wang X, Halbrook CJ, Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, Asara JM, Evans RM, Cantley LC, Lyssiotis CA, Kimmelman AC. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536(7617):479-83, 2016. e-Pub 2016. PMID: 27509858.
- Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun 7:10500, 2016. e-Pub 2016. PMID: 26806015.
- Klingler S, Guo B, Yao J, Yan H, Zhang L, Vaseva AV, Chen S, Canoll P, Horner JW, Wang YA, Paik JH, Ying H, Zheng H. Development of resistance to EGFR targeted therapy in malignant glioma can occur through EGFR dependent and independent mechanisms. Cancer Res 75(10):2109-2119, 2015. e-Pub 2015. PMID: 25808866.
- Pettazzoni P, Viale A, Shah P, Carugo A, Ying H, Wang H, Genovese G, Seth S, Minelli R, Green T, Huang-Hobbs E, Corti D, Sanchez N, Nezi L, Marchesini M, Kapoor A, Yao W, Francesco ME, Petrocchi A, Deem AK, Scott K, Colla S, Mills GB, Fleming JB, Heffernan TP, Jones P, Toniatti C, DePinho RA, Draetta GF. Genetic Events That Limit the Efficacy of MEK and RTK Inhibitor Therapies in a Mouse Model of KRAS-Driven Pancreatic Cancer. Cancer Res 75(6):1091-1101, 2015. e-Pub 2015. PMID: 25736685.
- Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 2014. e-Pub 2014. PMID: 25119024.
- Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158(1):185-97, 2014. e-Pub 2014. PMID: 24954535.
- Stopczynski RE, Normolle DP, Hartman DJ, Ying H, DeBerry JJ, Bielefeldt K, Rhim AD, DePinho RA, Albers KM, Davis BM. Neuroplastic changes occur early in the development of pancreatic ductal adenocarcinoma. Cancer Res 74(6):1718-27, 2014. e-Pub 2014. PMID: 24448244.
- Jun S, Lee S, Kim HC, Ng C, Schneider AM, Ji H, Ying H, Wang H, DePinho RA, Park JI. PAF-mediated MAPK signaling hyperactivation via LAMTOR3 induces pancreatic tumorigenesis. Cell Rep 5(2):314-22, 2013. e-Pub 2013. PMID: 24209743.
- Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC, Paik JH. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. EMBO J 32(19):2589-602, 2013. e-Pub 2013. PMID: 24013118.
- Zhang Y, Shin SJ, Liu D, Ivanova E, Foerster F, Ying H, Zheng H, Xiao Y, Chen Z, Protopopov A, Depinho RA, Paik JH. ZNF365 promotes stability of fragile sites and telomeres. Cancer Discov 3(7):798-811, 2013. e-Pub 2013. PMID: 23776040.
- Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496(7443):101-5, 2013. e-Pub 2013. PMID: 23535601.
- Du W, Yi Y, Zhang H, Bergholz J, Wu J, Ying H, Zhang Y, Xiao ZX. Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS One 8(4):e63179, 2013. e-Pub 2013. PMID: 23638184.
- Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2(8):736-49, 2012. e-Pub 2012. PMID: 22750848.
- Chen AJ, Paik JH, Zhang H, Shukla SA, Mortensen R, Hu J, Ying H, Hu B, Hurt J, Farny N, Dong C, Xiao Y, Wang YA, Silver PA, Chin L, Vasudevan S, Depinho RA. STAR RNA-binding protein Quaking suppresses cancer via stabilization of specific miRNA. Genes Dev 26(13):1459-72, 2012. e-Pub 2012. PMID: 22751500.
- Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-70, 2012. e-Pub 2012. PMID: 22541435.
- Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, Ding Z, Ying H, Boutin AT, Zhang H, Johnson S, Ivanova E, Kost-Alimova M, Protopopov A, Wang YA, Shirihai OS, Chin L, DePinho RA. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 148(4):651-63, 2012. e-Pub 2012. PMID: 22341440.
- Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W, Ren X, Zheng H, Kimmelman AC, Paik JH, Lim C, Perry SR, Jiang S, Malinn B, Protopopov A, Colla S, Xiao Y, Hezel AF, Bardeesy N, Turley SJ, Wang YA, Chin L, Thayer SP, DePinho RA. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov 1(2):158-69, 2011. e-Pub 2011. PMID: 21984975.
- Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, Kimmelman AC. Pancreatic cancers require autophagy for tumor growth. Genes Dev 25(7):717-29, 2011. e-Pub 2011. PMID: 21406549.
- Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, Wan L, Ang XL, Mock C, Yin H, Stommel JM, Gygi S, Lahav G, Asara J, Xiao ZX, Kaelin WG, Harper JW, Wei W. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 18(2):147-59, 2010. e-Pub 2010. PMID: 20708156.
- Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, Hu J, Vinjamoori A, Gan B, Sahin E, Chheda MG, Brennan C, Wang YA, Hahn WC, Chin L, DePinho RA. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 17(5):497-509, 2010. e-Pub 2010. PMID: 20478531.
- Ying H, Zheng H, Scott K, Wiedemeyer R, Yan H, Lim C, Huang J, Dhakal S, Ivanova E, Xiao Y, Zhang H, Hu J, Stommel JM, Lee MA, Chen AJ, Paik JH, Segatto O, Brennan C, Elferink LA, Wang YA, Chin L, DePinho RA. Mig-6 controls EGFR trafficking and suppresses gliomagenesis. Proc Natl Acad Sci U S A 107(15):6912-7, 2010. e-Pub 2010. PMID: 20351267.
- Paik JH, Ding Z, Narurkar R, Ramkissoon S, Muller F, Kamoun WS, Chae SS, Zheng H, Ying H, Mahoney J, Hiller D, Jiang S, Protopopov A, Wong WH, Chin L, Ligon KL, DePinho RA. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 5(5):540-53, 2009. e-Pub 2009. PMID: 19896444.
- Mineva ND, Wang X, Yang S, Ying H, Xiao ZX, Holick MF, Sonenshein GE. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol 220(3):593-9, 2009. e-Pub 2009. PMID: 19373868.
- Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, Ponugoti A, Nabioullin R, Deroo S, Yang S, Wang X, McGrath JP, Protopopova M, Ivanova E, Zhang J, Feng B, Tsao MS, Redston M, Protopopov A, Xiao Y, Futreal PA, Hahn WC, Klimstra DS, Chin L, DePinho RA. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A 105(49):19372-7, 2008. e-Pub 2008. PMID: 19050074.
- Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129-33, 2008. e-Pub 2008. PMID: 18948956.
- Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318(5848):287-90, 2007. e-Pub 2007. PMID: 17872411.
- Chang DL, Qiu W, Ying H, Zhang Y, Chen CY, Xiao ZX. ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene 26(32):4627-34, 2007. e-Pub 2007. PMID: 17297463.
- Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, Allday MJ, Xiao ZX. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 20(5):699-708, 2005. e-Pub 2005. PMID: 16337594.
- Murray SA, Yang S, Demicco E, Ying H, Sherr DH, Hafer LJ, Rogers AE, Sonenshein GE, Xiao ZX. Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors. J Cell Biochem 95(5):875-84, 2005. e-Pub 2005. PMID: 15844214.
- Ying H, Chang DL, Zheng H, McKeon F, Xiao ZX. DNA-binding and transactivation activities are essential for TAp63 protein degradation. Mol Cell Biol 25(14):6154-64, 2005. e-Pub 2005. PMID: 15988026.
- Currier N, Solomon SE, Demicco EG, Chang DL, Farago M, Ying H, Dominguez I, Sonenshein GE, Cardiff RD, Xiao ZX, Sherr DH, Seldin DC. Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol 33(6):726-37, 2005. e-Pub 2005. PMID: 16263698.
- Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K, Xiao ZX. The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. J Biol Chem 279(51):53317-22, 2004. e-Pub 2004. PMID: 15485814.
- Gu L, Ying H, Zheng H, Murray SA, Xiao ZX. The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Lett 544(1-3):218-22, 2003. e-Pub 2003. PMID: 12782320.
- Gu L, Zheng H, Murray SA, Ying H, Jim Xiao ZX. Deregulation of Cdc2 kinase induces caspase-3 activation and apoptosis. Biochem Biophys Res Commun 302(2):384-91, 2003. e-Pub 2003. PMID: 12604359.
Invited Articles
- Ying H, DePinho RA. Cancer signaling: when phosphorylation meets methylation. Cell Res 24(11):1282-3, 2014. e-Pub 2014. PMID: 25104733.
- Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, dePinho RA. Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. Cold Spring Harb Symp Quant Biol 73:427-37, 2008. e-Pub 2008. PMID: 19150964.
- Ying H, Xiao ZX. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 5(5):506-8, 2006. e-Pub 2006. PMID: 16552188.
Review Articles
- Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 39(1-2):36-63, 2025. e-Pub 2025. PMID: 39510840.
- Yang Z, Chen S, Ying H, Yao W. Targeting syndecan-1: new opportunities in cancer therapy. Am J Physiol Cell Physiol 323(1):C29-C45, 2022. e-Pub 2022. PMID: 35584326.
- Yao W, Maitra A, Ying H. Recent insights into the biology of pancreatic cancer. EBioMedicine 53:102655, 2020. e-Pub 2020. PMID: 32139179.
- Yan L, Raj P, Yao W, Ying H. Glucose Metabolism in Pancreatic Cancer. Cancers (Basel) 11(10), 2019. e-Pub 2019. PMID: 31569510.
- Mann KM, Ying H, Juan J, Jenkins NA, Copeland NG. KRAS-related proteins in pancreatic cancer. Pharmacol Ther 168:29-42, 2016. e-Pub 2016. PMID: 27595930.
- Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 30(4):355-85, 2016. e-Pub 2016. PMID: 26883357.
Book Chapters
- Yao W, Ying H. The Prospects of Immunotherapy in Pancreatic Cancer. In: Pancreatic Cancer: A Multidisciplinary Approach. Springer, 269-282, 2022.
Letters to the Editor
- Yousef M, Yousef A, Hurd MW, Pillai A, Chowdhury S, Snyder R, Knafl M, Lewis RL, Roy PM, Fanaeian M, Albarouki S, Castelnovo LF, Peterson J, Smaglo BG, Wolff RA, Pant S, Willis J, Huey R, Overman M, Tzeng CW, Kim MP, Ikoma N, Maxwell JE, Katz MHG, Wang H, Maitra A, Koay E, Ludmir EB, Chen A, Lopez C, Ying H, Shen JP, Zhao D. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. J Hematol Oncol 18: 44, 2025.
Patents
- DePinho RA, Cantley L, Kimmelman AC, Ying H, Lyssiotis CA. Methods for diagnosing and treating oncogenic Kras-associated cancer, 2015. Patent Number: 9,745,631.
Patient Reviews
CV information above last modified March 10, 2026